Hartmann Tanja N, Leick Marion, Ewers Susann, Diefenbacher Andrea, Schraufstatter Ingrid, Honczarenko Marek, Burger Meike
Department of Internal Medicine, Freiburg University Clinic, Freiburg, Germany.
Immunology. 2008 Oct;125(2):252-62. doi: 10.1111/j.1365-2567.2008.02836.x. Epub 2008 Apr 4.
Chemokines orchestrate the organization of leucocyte recruitment during inflammation and homeostasis. Despite growing knowledge of chemokine receptors, some orphan chemokine receptors are still not characterized. The gene CCRL2 encodes such a receptor that exists in two splice variants, CRAM-A and CRAM-B. Here, we report that CRAM is expressed by human peripheral blood and bone marrow B cells, and by different B-cell lines dependent on the B-cell maturation stage. Intriguingly, CRAM surface expression on the pre-B-cell lines Nalm6 and G2 is specifically upregulated in response to the inflammatory chemokine CCL5 (RANTES), a chemokine that is well known to play an important role in modulating immune responses. Although Nalm6 cells do not express any of the known CCL5 binding receptors, extracellular signal-regulated kinases 1 and 2 (ERK1/2) are phosphorylated upon CCL5 stimulation, suggesting a direct effect of CCL5 through the CRAM receptor. However, no calcium mobilization or migratory responses upon CCL5 stimulation are induced in B-cell lines or in transfected cells. Also, ERK1/2 phosphorylation cannot be inhibited by pertussis toxin, suggesting that CRAM does not couple to Gi proteins. Our results describe the expression of a novel, non-classical chemokine receptor on B cells that is potentially involved in immunomodulatory functions together with CCL5.
趋化因子在炎症和内环境稳态过程中协调白细胞募集的组织。尽管对趋化因子受体的了解不断增加,但一些孤儿趋化因子受体仍未得到表征。基因CCRL2编码这样一种受体,它以两种剪接变体CRAM-A和CRAM-B存在。在此,我们报告CRAM在人外周血和骨髓B细胞以及依赖于B细胞成熟阶段的不同B细胞系中表达。有趣的是,前B细胞系Nalm6和G2上的CRAM表面表达在炎症趋化因子CCL5(RANTES)刺激下特异性上调,CCL5是一种众所周知在调节免疫反应中起重要作用的趋化因子。虽然Nalm6细胞不表达任何已知的CCL5结合受体,但在CCL5刺激下细胞外信号调节激酶1和2(ERK1/2)会被磷酸化,这表明CCL5通过CRAM受体产生直接作用。然而,在B细胞系或转染细胞中,CCL5刺激不会诱导钙动员或迁移反应。此外,百日咳毒素不能抑制ERK1/2磷酸化,这表明CRAM不与Gi蛋白偶联。我们的结果描述了一种新型非经典趋化因子受体在B细胞上的表达,它可能与CCL5一起参与免疫调节功能。